Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
166.81+1.36 (+0.82%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close165.45
Bid165.55 x 100
Ask168.68 x 400
Day's Range165.26 - 167.72
52wk Range138.06 - 176.85
1y Target EstN/A
Market Cap124.83B
P/E Ratio (ttm)17.07
Avg Vol (3m)2,849,579
Dividend & Yield4.00 (2.42%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reuters17 hours ago

    Novartis psoriasis drug maintains efficacy after 4 years - study

    Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved "clear or almost clear" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.

  • Prothena Builds On Psoriasis Science For Arthritis Treatment
    Investor's Business Dailyyesterday

    Prothena Builds On Psoriasis Science For Arthritis Treatment

    Prothena said late Thursday that it plans to launch phase two testing for a psoriatic arthritis drug.

  • Benzingayesterday

    Chardan Rates Regeneron A Sell, Advises Caution

    Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) top line results from a mid-stage study of Eylea co-formulated with rinuccumab didn't meet its primary endpoint. Chardan's Sell rating was predicated on risks ...